From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Sat, 22 Feb 2020 19:41:48 +0000

To: Cassetti, Cristina (NIH/NIAID) [E]

Subject: RE: HHS Engages Sanofi’s Recombinant Technology for 2019 Novel Coronavirus
Vaccine

Thanks.

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

 

Phone: |
FAX: (301) 496-4409

Sl, San 1

The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E]f—__ @) @>

Sent: Saturday, February 22, 2020 2:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [>
Cc: Erbelding, Emily (NIH/NIAID) (EJ YC} >

Subject: Fwd: HHS Engages Sanofi’s Recombinant Technology for 2019 Novel Coronavirus Vaccine

 

This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts
Cristina

Begin forwarded message:

From: "Folkers, Greg (NIH/NIAID) [E]" (<q

Date: February 18, 2020 at 3:07:21 PM EST
Subject: HHS Engages Sanofi’s Recombinant Technology for 2019 Novel Coronavirus
Vaccine

FOR IMMEDIATE RELEASE
February 18, 2020
Contact: ASPR Press Office
202-205-8117

asprmedia@hhs.gov

NIH-001639
